Skip to main content
Top
Published in: European Radiology 5/2009

01-05-2009 | Hepatobiliary-Pancreas

Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation

Authors: A. R. Gillams, W. R. Lees

Published in: European Radiology | Issue 5/2009

Login to get access

Abstract

There is little published long-term survival data for patients with colorectal liver metastases treated with radiofrequency ablation (RFA). We present a multivariate analysis of 5-year survival in 309 patients (198 male, aged 64 (24–92)) treated at 617 sessions. Our standard protocol used internally cooled electrodes introduced percutaneously under combined US and CT guidance/monitoring. The number and size of liver metastases, the presence and location of extrahepatic disease, primary resection, clinical, chemotherapy and follow-up data were recorded. Data analysis was performed using SPSS v.10. On multivariate analysis, significant survival factors were the presence of extrahepatic disease (p < 0.001) and liver tumour volume (p = 0.001). For 123 patients with five or less metastases of 5 cm or less maximum diameter and no extrahepatic disease median survival was 46 and 36 months from liver metastasis diagnosis and ablation, respectively; corresponding 3- and 5-year survival rates were 63%, 34% and 49%, 24%. Sixty-nine patients had three or less tumours of below 3.5 cm in diameter and their 5-year survival from ablation was 33%. There were 23/617(3.7%) local complications requiring intervention. Five-year survival of 24–33% post ablation in selected patients is superior to any published chemotherapy data and approaches the results of liver resection.
Literature
1.
go back to reference Steward BW, Kleihues P (eds) (2003) Colorectal cancer. World cancer report. IACR, Lyon, pp 198–202 Steward BW, Kleihues P (eds) (2003) Colorectal cancer. World cancer report. IACR, Lyon, pp 198–202
2.
go back to reference Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766PubMedCrossRef Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766PubMedCrossRef
3.
go back to reference Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D’Angelica M (2007) Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 14:1151–1160PubMedCrossRef Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D’Angelica M (2007) Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 14:1151–1160PubMedCrossRef
4.
go back to reference Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825PubMedCrossRef Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825PubMedCrossRef
5.
go back to reference Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047PubMedCrossRef Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047PubMedCrossRef
6.
go back to reference Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147PubMed Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147PubMed
7.
go back to reference Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef
8.
go back to reference Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni A (2008) A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 98:71–76PubMedCrossRef Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni A (2008) A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 98:71–76PubMedCrossRef
9.
go back to reference Gillams AR, Lees WR (2004) Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 14:2261–2267PubMedCrossRef Gillams AR, Lees WR (2004) Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 14:2261–2267PubMedCrossRef
10.
go back to reference Gillams AR, Lees WR (2000) Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum 43:656–661PubMedCrossRef Gillams AR, Lees WR (2000) Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum 43:656–661PubMedCrossRef
11.
go back to reference Vogl TJ, Mack MG, Roggan A, Straub R, Eichler KC, Muller PK, Knappe V, Felix R (1998) Internally cooled power laser for MR-guided interstitial laser-induced thermotherapy of liver lesions: initial clinical results. Radiology 209:381–385PubMed Vogl TJ, Mack MG, Roggan A, Straub R, Eichler KC, Muller PK, Knappe V, Felix R (1998) Internally cooled power laser for MR-guided interstitial laser-induced thermotherapy of liver lesions: initial clinical results. Radiology 209:381–385PubMed
12.
go back to reference Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD III, Dupuy DE, Gervais D, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan J, Phillips DA, Rhim H, Silverman SG (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 235:728–739PubMedCrossRef Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD III, Dupuy DE, Gervais D, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan J, Phillips DA, Rhim H, Silverman SG (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 235:728–739PubMedCrossRef
13.
go back to reference Jakobs TF, Hoffmann RT, Trumm C, Reiser MF, Helmberger TK (2006) Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer Res 26:671–680PubMed Jakobs TF, Hoffmann RT, Trumm C, Reiser MF, Helmberger TK (2006) Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer Res 26:671–680PubMed
14.
go back to reference Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221:159–166PubMedCrossRef Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221:159–166PubMedCrossRef
15.
go back to reference Sorensen SM, Mortensen FV, Nielsen DT (2007) Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 48:253–258PubMedCrossRef Sorensen SM, Mortensen FV, Nielsen DT (2007) Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 48:253–258PubMedCrossRef
16.
go back to reference Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK (2006) Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141:460–466PubMedCrossRef Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK (2006) Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141:460–466PubMedCrossRef
17.
go back to reference Abitabile P, Hartl U, Lange J, Maurer CA (2007) Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 33:67–71PubMed Abitabile P, Hartl U, Lange J, Maurer CA (2007) Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 33:67–71PubMed
18.
go back to reference Siperstein AE, Berber E, Ballem N, Parikh RT (2007) Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 246:559–565PubMedCrossRef Siperstein AE, Berber E, Ballem N, Parikh RT (2007) Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 246:559–565PubMedCrossRef
19.
go back to reference Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW (2006) Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 12:318–326PubMedCrossRef Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW (2006) Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 12:318–326PubMedCrossRef
20.
go back to reference Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P (2003) Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 90:567–574PubMedCrossRef Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P (2003) Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 90:567–574PubMedCrossRef
21.
go back to reference Yamada H, Kondo S, Okushiba S, Morikawa T, Katoh H (2001) Analysis of predictive factors for recurrence after hepatectomy for colorectal liver metastases. World J Surg 25:1129–1133PubMed Yamada H, Kondo S, Okushiba S, Morikawa T, Katoh H (2001) Analysis of predictive factors for recurrence after hepatectomy for colorectal liver metastases. World J Surg 25:1129–1133PubMed
22.
go back to reference Bakalakos EA, Kim JA, Young DC, Martin EW Jr (1998) Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg 22:399–404PubMedCrossRef Bakalakos EA, Kim JA, Young DC, Martin EW Jr (1998) Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg 22:399–404PubMedCrossRef
23.
go back to reference Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C (1996) Patient selection for hepatic resection of colorectal metastases. Arch Surg 131:322–329PubMed Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C (1996) Patient selection for hepatic resection of colorectal metastases. Arch Surg 131:322–329PubMed
24.
go back to reference Ahmed M, Goldberg SN (2004) Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia 20:781–802PubMedCrossRef Ahmed M, Goldberg SN (2004) Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia 20:781–802PubMedCrossRef
Metadata
Title
Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation
Authors
A. R. Gillams
W. R. Lees
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
European Radiology / Issue 5/2009
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-008-1258-5

Other articles of this Issue 5/2009

European Radiology 5/2009 Go to the issue